Oxytocin and opioid antagonists for treatment of social dysfunction disorder

The present invention relates to the discovery that co-administration of both oxytocin (OT) and at least one opioid antagonist can increase social function in a subject. In certain embodiments, the co-administration can be used to treat one or more social dysfunction disorders in a subject, including, but not limited to autism, schizophrenia, anxiety disorders, and post-traumatic stress disorder (PTSD). In other embodiments, the OT and the opioid antagonist can be co-administered to a subject as an aerosolized pharmaceutical composition.